Table 1.

Antitumor activity of sorafenib in combination with erlotinib or cetuximab in H1299 human cancer xenografts

TreatmentAverage tumor volume (±SD) on day 35 after tumor cell injection, cm3Average survival (±SD), days
Control2.5 (±0.2)35 (±2)
Erlotinib2.5 (±0.3)37 (±4)
Sorafenib0.56 (±0.01)75 (±5)
Cetuximab2.55 (±0.2)34 (±5)
Erlotinib plus sorafenib0.15 (±0.04)145 (±5)
Cetuximab plus sorafenib0.10 (±0.03)165 (±10)

NOTE: Each treatment (erlotinib, sorafenib, cetuximab, erlotinib plus sorafenib, or cetuximab plus sorafenib) was started on day 7 following H1299 tumor cell s.c. injection when the average tumor volume was 0.30 (±0.05) cm3.

Erlotinib treatment: 75 mg/kg/dose orally 5 days/week starting on the day 7 following tumor cell injection.

Sorafenib treatment: 50 mg/kg/dose orally 5 days/week starting on the day 7 following tumor cell injection.

Cetuximab treatment: 1 mg/dose i.p. twice weekly starting on the day 7 following tumor cell injection.

Treatment was done for 4 weeks. Each group consisted of 10 mice.

Mice were sacrificed when tumor volume reached 2.5 cm3 (approximately 10% of a nude mouse body weight).